Barclays
ONCT

Barclays’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Barclays’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-72
Closed -$16K – 7454
2018
Q3 		$16K Buy
+72
New +$173K ﹤0.01% 6533
2014
Q2 		– Sell
-7
Closed -$10K – 7852
2014
Q1 		$10K Sell
7
-1
-13% -$2.49K ﹤0.01% 6938
2013
Q4 		$12K Sell
8
-45
-85% -$103K ﹤0.01% 6943
2013
Q3 		$148K Buy
53
+21
+66% +$104K ﹤0.01% 5305
2013
Q2 		$292K Buy
+32
New +$247K ﹤0.01% 4810

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barclays's ONCT Position: Q3 2022 in Review

Barclays sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 181 shares — an estimated $4K sold.

Barclays first reported a position in ONCT in Q2 2013 and held it in 17 quarters. The position peaked at $496K in Q2 2013. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Barclays reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 181 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
  • Barclays first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
  • Barclays's Oncternal Therapeutics, Inc. Common Stock position peaked at $496K in Q2 2013.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.